Related Experiment Video
Updated: Jun 9, 2025
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Preterm Infant with Generalized Arterial Calcification of Infancy Who Survived Due to Early Diagnosis and Appropriate
Masato Tanaka1, Akira Kobayashi1, Haruhiro Kuwabara1
1Department of Pediatrics, Niigata University Medical and Dental Hospital, Niigata 951-8514, Japan.
Insights
Generalized arterial calcification of infancy (GACI) is a rare, severe condition. Early diagnosis and adjusted bisphosphonate dosing in preterm infants can improve cardiac function and survival rates.
Area of Science:
- Pediatric Cardiology
- Genetics
- Neonatology
Background:
- Generalized arterial calcification of infancy (GACI) is a rare genetic disorder causing severe arterial calcification, hypertension, and heart failure, with high mortality in infants.
- Mutations in ENPP1 or ABCC6 genes are the primary cause of GACI.
- Preterm infants with GACI face heightened risks due to immature cardiac function.
Observation:
- A case study involving a preterm infant (30 weeks gestation) diagnosed with GACI based on arterial high-intensity lesions and widespread calcification.
- Initial treatment with intravenous pamidronate showed temporary improvement in cardiac contraction.
- Worsening cardiac function after one month necessitated a reduced dosing interval of pamidronate, leading to improved cardiac function.
Findings:
- Adjusting the dosing interval of intravenous pamidronate was crucial for sustained cardiac improvement in a preterm GACI patient.
- Transitioning to oral etidronate was part of the long-term management strategy.
- Early diagnosis through imaging and prompt, tailored bisphosphonate therapy are key.
Implications:
- This case highlights the need for individualized bisphosphonate treatment regimens in preterm infants with GACI.
- Optimizing treatment protocols can potentially reduce morbidity and mortality associated with GACI in this vulnerable population.
- Further research into standardized, effective treatment strategies for GACI is warranted.
Abstract:
Generalized arterial calcification of infancy (GACI) is a rare disease characterized by arterial calcification. GACI is caused by a mutation in the ENPP1 or ABCC6 genes. GACI causes severe hypertension and heart failure, and approximately 50% of patients die within the first 6 months. In particular, preterm infants with GACI often die due to immature cardiac function. Bisphosphonates are effective in treating GACI; however, no standardized treatment regimen is available. We experienced a case of a preterm infant with GACI born at 30 weeks gestation. Ultrasonography showed high-intensity lesions in the arteries, and computed tomography revealed calcification of the arteries throughout the body, leading to the diagnosis of GACI. We administered intravenous pamidronate, and her cardiac contraction improved. The initial scheduled interval between drug administrations was 2 months. However, the cardiac contraction worsened 1 month after the pamidronate administration. Therefore, we decreased the dosing interval and administered a second course of pamidronate, which improved her cardiac function. We then switched to oral etidronate. To improve the morbidity and mortality rates of preterm infants with GACI, it is important to obtain an early diagnosis of GACI by investigating high-intensity lesions in the arteries and performing early administration of an appropriate type of bisphosphonate.
More Related Videos
08:43Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
